The estimated Net Worth of J. Anthony Ware is at least $585 Thousand dollars as of 15 June 2024. Mr. Ware owns over 3,900 units of AnaptysBio Inc stock worth over $267,000 and over the last 7 years he sold ANAB stock worth over $0. In addition, he makes $317,736 as Independent Director at AnaptysBio Inc.
J has made over 2 trades of the AnaptysBio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,900 units of ANAB stock worth $138,840 on 15 June 2024.
The largest trade he's ever made was exercising 3,900 units of AnaptysBio Inc stock on 15 June 2024 worth over $138,840. On average, J trades about 750 units every 165 days since 2017. As of 15 June 2024 he still owns at least 7,500 units of AnaptysBio Inc stock.
You can see the complete history of Mr. Ware stock trades at the bottom of the page.
J. Anthony Ware M.D. serves as Independent Director of the Company.D. serves as Independent Director of the Company. From 2001 to January 2018, Dr. Ware held numerous positions at Eli Lilly and Company, a global pharmaceutical company, including Senior Vice President of Product Development of Lilly Bio-Medicines from October 2009 to January 2018 and Interim President of Lilly Bio-Medicines from January 2017 to April 2017. Before joining Eli Lilly and Company, Dr. Ware served as Professor of Medicine and Molecular Pharmacology at Albert Einstein College of Medicine in New York, where he was also Chief of Cardiology at Montefiore Medical Center from 1996 to 2001. Before joining Albert Einstein College of Medicine, Dr. Ware was on the faculty of Harvard Medical School from 1984 to 1996 and served as a senior physician and Director of the Coronary Care Unit at Beth Israel Hospital. Dr. Ware received his B.S. from Washburn University, his M.D. from the University of Kansas. He completed internships and residency at The University of Texas at Houston and Baylor College of Medicine, where he also served as Chief Resident. He completed fellowships both at Baylor and at Harvard Medical School, and is board certified both in internal medicine and cardiovascular disease. Our board of directors believes that Dr. Ware’s extensive academic and industry experience and significant knowledge of scientific matters provide him with the qualifications and skills to serve on our board of directors.
As the Independent Director of AnaptysBio Inc, the total compensation of J Ware at AnaptysBio Inc is $317,736. There are 8 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.
J Ware is 67, he's been the Independent Director of AnaptysBio Inc since 2017. There are 2 older and 12 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.
J's mailing address filed with the SEC is 10421 Pacific Center Ct, San Diego, CA 92121, USA.
Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1, and James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.
founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
AnaptysBio Inc executives and other stock owners filed with the SEC include: